论文部分内容阅读
作者对10例恶性贫血患者的血小板大小,血小板聚集及出血时间作了研究,并观察了V_(B12)治疗对这些指标的影响。结果发现10例中有6例对肾上腺素,3例对纤维蛋白原、2例对二磷酸腺苷(ADP),2例对Ristocetin引起的血小板聚集异常,有3例出血时间延长,5例血小板数减少,而经V_(B12)治疗后这些异常均被纠正。甚至有3例出现暂时性血小板增多现象。血小板大小在治疗前后是有改变的,治疗后出现相当多的小型血小板(P<0.05),但与正常比较,无明显差别。V_(B12)缺乏患者的骨髓主要缺陷好像是早期血细胞不能合成足够的DNA,从而导致各系细胞减少。通过加入正常血浆不能改变Ristocetin引起血
The authors studied platelet size, platelet aggregation and bleeding time in 10 patients with pernicious anemia and observed the effects of V_ (B12) treatment on these indices. RESULTS: Six of 10 patients had abnormalities in platelet aggregation caused by epinephrine, 3 with fibrinogen, 2 with adenosine diphosphate (ADP), 2 with Ristocetin, 3 with prolonged bleeding, 5 with platelet However, all the abnormalities were corrected after V_ (B12) treatment. There are even three cases of transient thrombocytosis phenomenon. Platelet size changed before and after treatment, and there were quite a few small platelets after treatment (P <0.05). However, there was no significant difference between the two groups. The major deficiency of V_ (B12) in patients with bone marrow seems to be that early blood cells can not synthesize enough DNA, resulting in a decrease in the number of cells in each lineage. Ristocetin can not cause blood changes by adding normal plasma